Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial …
PR Web (press release)
Research Reports in Clinical Cardiology has published “Galectin-3: clinical utility and prognostic value in patients with heart failure“. This review summarizes the key findings of fourteen clinical trials in which Galectin-3 (Gal-3) was assessed as a …

and more »

Unmet Medical Need in Treatment of Heart Failure Patients with Atrial …
PharmiWeb.com (press release)
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation, heart failure and other cardiovascular diseases, today announced that the editorial ‚ÄúTreatment of the Heart Failure …

and more »

Public speaking guru, New York professor Ramon Bagasan dies of heart failure …
GMA News
Public speaking guru and longtime New York professor Ramon N. Bagasan, Esq. died of heart failure on Jan. 30 at North Shore-Long Island Jewish Medical Center. He was 85. Born on Oct. 10, 1927 in Meycauayan, Bulacan, Bagasan taught at St. John’s …

and more »

Novel Catheter-Based Treatment for Heart Failure Begins US Trial
Angioplasty.Org
February 6, 2013 — CardioKinetix, Inc., a medical device company, based in Menlo Park, California, recently announced the start of a major U.S.-based trial for their Parachute™ Ventricular Partitioning Device, the first catheter-based treatment for …

Unmet Medical Need In Treatment Of Heart Failure Patients With Atrial …
TheStreet.com (press release)
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation, heart failure and other cardiovascular diseases, today announced that the editorial “Treatment of the Heart Failure …

and more »

Unmet Medical Need in Treatment of Heart Failure Patients with Atrial …
Fort Mills Times
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation, heart failure and other cardiovascular diseases, today announced that the editorial “Treatment of the Heart Failure …

and more »

Unmet Medical Need in Treatment of Heart Failure Patients with Atrial …
Business Wire (press release)
BUSINESS WIRE)–ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation, heart failure and other cardiovascular diseases, today announced that the editorial “Treatment of the …

and more »

Mayo Clinic-led study identifies biomarkers for early risk assessment of acute …
Science Codex
ROCHESTER, Minn. — Acute kidney injury strikes large numbers of hospitalized patients, including those with no prior kidney-related illness, and is one of the most costly and deadly conditions affecting critically ill patients. Findings published …
Research Validates New Biomarkers For Risk Assessment Of Acute Kidney InjuryPR Newswire (press release)
Astute Medical, Inc. Advancing Next Generation Acute Kidney Injury BiomarkersInternational Business Times (press release)
Discovery and validation of cell cycle arrest biomarkers in human acute kidney …7thSpace Interactive (press release)
MedPage Today
all 5 news articles »

Study Identifies Biomarkers for Early Risk Assessment of Acute Kidney Injury
Newswise (press release)
Newswise — ROCHESTER, Minn. — Acute kidney injury strikes large numbers of hospitalized patients, including those with no prior kidney-related illness, and is one of the most costly and deadly conditions affecting critically ill patients. Findings …
Research Validates New Biomarkers For Risk Assessment Of Acute Kidney InjuryPR Newswire (press release)
Astute Medical, Inc. Advancing Next Generation Acute Kidney Injury BiomarkersInternational Business Times (press release)
Discovery and validation of cell cycle arrest biomarkers in human acute kidney …7thSpace Interactive (press release)
MedPage Today
all 5 news articles »